Prescient advances PTX-100 clinical program with key European regulatory wins
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics CEO James McDonnell talked with Proactive about the company’s clinical and regulatory progress...
Prescient Therapeutics Ltd (ASX: PTX) earlier this week received European authorisation to begin clinical trials...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
In a sector where the right drug emerging at the right time can yield billions, Prescient...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the company’s latest milestone —...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is targeting A$7 million through a Share Purchase Plan (SPP) to...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.